Dayuan Shi1,2,3,4, Jiawei Xu5,6,7,8, Wenbin Niu1,2,3,4, Yidong Liu1,2,3,4, Hao Shi1,2,3,4, Guidong Yao1,2,3,4, Senlin Shi1,2,3,4, Gang Li1,2,3,4, Wenyan Song1,2,3,4, Haixia Jin1,2,3,4, Yingpu Sun9,10,11,12. 1. Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 2. Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 3. Henan Provincial Obstetrical and Gynecological Diseases (Reproductive Medicine) Clinical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 4. Henan Engineering Laboratory of Preimplantation Genetic Diagnosis and Screening, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 5. Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. jiawxu@foxmail.com. 6. Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. jiawxu@foxmail.com. 7. Henan Provincial Obstetrical and Gynecological Diseases (Reproductive Medicine) Clinical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. jiawxu@foxmail.com. 8. Henan Engineering Laboratory of Preimplantation Genetic Diagnosis and Screening, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. jiawxu@foxmail.com. 9. Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. syp2008@vip.sina.com. 10. Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. syp2008@vip.sina.com. 11. Henan Provincial Obstetrical and Gynecological Diseases (Reproductive Medicine) Clinical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. syp2008@vip.sina.com. 12. Henan Engineering Laboratory of Preimplantation Genetic Diagnosis and Screening, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. syp2008@vip.sina.com.
Abstract
PURPOSE: The preimplantation genetic testing for monogenic defects (PGT-M) is a beneficial strategy for the patients suffering from a Mendelian disease, which could protect their offspring from inheriting the disease. The purpose of this study is to report the effectiveness of PGT-M based on karyomapping for three cases of dynamic mutation diseases with trinucleotide repeat expansion. METHODS: PGT-M was carried out on three couples, whose family members were diagnosed with Huntington's disease or spinocerebellar ataxias 2 or 12. The whole genome amplification was obtained using the multiple displacement amplification (MDA) method. Then, karyomapping was performed to detect the allele that is carrying the trinucleotide repeat expansion using single nucleotide polymorphism (SNP) linkage analyses, and the copy number variations (CNVs) of the embryos were also identified. Prenatal diagnosis was performed to validate the accuracy of PGT-M. RESULTS: PGT-M was successfully performed on the three couples, and they accepted the transfers of euploid blastocysts without the relevant pathogenic allele. The clinical pregnancies were acquired and the prenatal diagnosis of the three families confirmed the effectiveness of karyomapping. The three born babies were healthy and free of the pathogenic alleles HTT, ATXN2, or PPP2R2B corresponding to Huntington's disease, spinocerebellar ataxias 2 or 12, respectively. CONCLUSION: This study shows that karyomapping is a highly powerful and efficient approach for dynamic mutation detection in preimplantation embryos. In this work, we first report the birth of healthy babies that are free of the pathogenic gene for dynamic mutation diseases in patients receiving PGT-M by karyomapping.
PURPOSE: The preimplantation genetic testing for monogenic defects (PGT-M) is a beneficial strategy for the patients suffering from a Mendelian disease, which could protect their offspring from inheriting the disease. The purpose of this study is to report the effectiveness of PGT-M based on karyomapping for three cases of dynamic mutation diseases with trinucleotide repeat expansion. METHODS: PGT-M was carried out on three couples, whose family members were diagnosed with Huntington's disease or spinocerebellar ataxias 2 or 12. The whole genome amplification was obtained using the multiple displacement amplification (MDA) method. Then, karyomapping was performed to detect the allele that is carrying the trinucleotide repeat expansion using single nucleotide polymorphism (SNP) linkage analyses, and the copy number variations (CNVs) of the embryos were also identified. Prenatal diagnosis was performed to validate the accuracy of PGT-M. RESULTS: PGT-M was successfully performed on the three couples, and they accepted the transfers of euploid blastocysts without the relevant pathogenic allele. The clinical pregnancies were acquired and the prenatal diagnosis of the three families confirmed the effectiveness of karyomapping. The three born babies were healthy and free of the pathogenic alleles HTT, ATXN2, or PPP2R2B corresponding to Huntington's disease, spinocerebellar ataxias 2 or 12, respectively. CONCLUSION: This study shows that karyomapping is a highly powerful and efficient approach for dynamic mutation detection in preimplantation embryos. In this work, we first report the birth of healthy babies that are free of the pathogenic gene for dynamic mutation diseases in patients receiving PGT-M by karyomapping.
Authors: Liying Yan; Lei Huang; Liya Xu; Jin Huang; Fei Ma; Xiaohui Zhu; Yaqiong Tang; Mingshan Liu; Ying Lian; Ping Liu; Rong Li; Sijia Lu; Fuchou Tang; Jie Qiao; X Sunney Xie Journal: Proc Natl Acad Sci U S A Date: 2015-12-28 Impact factor: 11.205
Authors: K Sermon; S Seneca; M De Rycke; V Goossens; H Van de Velde; A De Vos; P Platteau; W Lissens; A Van Steirteghem; I Liebaers Journal: Mol Cell Endocrinol Date: 2001-10-22 Impact factor: 4.102
Authors: Ronald A M Buijsen; Lodewijk J A Toonen; Sarah L Gardiner; Willeke M C van Roon-Mom Journal: Neurotherapeutics Date: 2019-04 Impact factor: 7.620